IN PATIENTS WITH ANKYLOSING SPONDYLITIS (AS), ADALIMUMAB IMPROVES INFLAMMATORY BOWEL DISEASE (IBD) AND PSORIASIS (Ps) AND PREVENTS ANTERIOR UVEITIS (AU) FLARES

Samankaltaisia teoksia

• Adalimumab (HUMIRA (R)) improves inflammatory bowel disease (IBD) and psoriasis (Ps) and prevents anterior uveitis (AU) flares in patients with Ankylosing spondylitis (AS)
  Tekijä: Rudwaleit, M, et al.
  Julkaistu: (2008)
• Predictors of good clinical response (BASDAI 50 or ASAS partial remission) in 1,250 patients treated with adalimumab (humira (R)) for active ankylosing spondylitis (AS)
  Tekijä: Rudwaleit, M, et al.
  Julkaistu: (2008)
• Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis.
  Tekijä: Rudwaleit, M, et al.
  Julkaistu: (2009)
• Adalimumab is effective and well-tolerated in patients with ankylosing spondylitis (AS) in day-to-day clinical practice - Results from rhapsody
  Tekijä: Wordsworth, P, et al.
  Julkaistu: (2008)
• Efficacy of adalimumab in uveitis in patients with ankylosing spondylitis
  Tekijä: Shandor Fedorovich Erdes
  Julkaistu: (2012-03-01)